| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938a6d7a15cbc93a74abe1953eb25d47 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045 |
| filingDate |
2021-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93957476f7da883fa3dd24c460975781
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7364a39f6174d52eed20b2f789f68ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5b837bd8ea0b8cb6d10ec0b8f272648
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f07f190f1bd5bca485c130a899eddba7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26329f695ecd0bbd0537e60ddec88a80 |
| publicationDate |
2021-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-3173808-A1 |
| titleOfInvention |
Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| abstract |
This application describes methods of inhibiting APOL1 and treating APOL1-mediated diseases comprising administering Compound I and/or a pharmaceutically acceptable salt thereof. Compound I The application also describes pharmaceutical compositions comprising Compound I and/or a pharmaceutically acceptable salt thereof. |
| priorityDate |
2020-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |